Osteonecrosis of the Jaw (ONJ) Might Explain the Increased Oral Surgery Risk in Cancer Patients Treated with Bisphosphonates

Journal of Evidence-Based Dental Practice

Volumn 7, Issue 3, 2007, Pages 132-135

  Van den Wyngaert, Tim ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 35448951819     PISSN: 15323382     EISSN: 15323390     Source Type: Journal    
DOI: 10.1016/j.jebdp.2007.05.013     Document Type: Note

References (14)

1. Rogers M.J., Gordon S., Benford H.L., et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88 12 Suppl (2000) 2961-2978
2. Ross J.R., Saunders Y., Edmonds P.M., Patel S., Broadley K.E., and Johnston S.R. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ 327 7413 (2003) 469-474
3. Reszka A.A., and Rodan G.A. Bisphosphonate mechanism of action. Curr Rheumatol Rep 5 1 (2003) 65-74
4. Marx R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61 9 (2003) 1115-1117
5. Van den Wyngaert T., Huizing M.T., and Vermorken J.B. Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy?. Ann Oncol 17 8 (2006) 1197-1204
6. Fleisch H. Bisphosphonates in bone disease. 2nd ed. (1995), The Parthenon Publishing Group, New York
7. Ruggiero S.L., Fantasia J., and Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102 4 (2006) 433-441
8. Michaud L.B., and Goodin S. Cancer-treatment-induced bone loss, part 2. Am J Health Syst Pharm 63 6 (2006) 534-546
9. Katagiri H., Takahashi M., Wakai K., Sugiura H., Kataoka T., and Nakanishi K. Prognostic factors and a scoring system for patients with skeletal metastasis. J Bone Joint Surg Br 87 5 (2005) 698-703
10. Ruggiero S.L., and Mehrotra B. Ten years of alendronate treatment for osteoporosis in postmenopausal women. N Engl J Med 351 352 (2004) 190-192
11. Mehrotra B., and Ruggiero S. Bisphosphonate complications including osteonecrosis of the jaw. Hematology Am Soc Hematol Educ Program (2006) 356-360
12. Hoff A.O., Toth B.B., Altundag K., et al. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. J Clin Oncol 24 18suppl (2006) 8528
13. Zervas K., Verrou E., Teleioudis Z., et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 134 6 (2006) 620-623
14. Berenson J.R., Hillner B.E., Kyle R.A., et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 20 17 (2002) 3719-3736